US IPO Week Ahead: August IPO market opens with biotechs, a bank, and SpaceX earnings
The article previews four US IPOs scheduled for the coming week: Braveheart Bio (BRVE) raising $300M at a $1.4B market cap, Attovia Therapeutics (ATTO) raising $200M at $649M, River City Bank (RCBC) raising $136M at $703M, and Vogenx (VOGX) raising $75M at $173M. It also notes SpaceX (SPCX) earnings and a partial lock-up release that will expand tradable float.
How this was made
The 30-second read
Why it matters
The only potentially time-sensitive catalyst with trading implications is SpaceX’s first public-company earnings combined with a partial lock-up release that increases tradable float. The IPO entries are primarily forward-looking raise and pipeline timelines without new results.
Market read
Traders may use the calendar for event timing, but the article lacks new pricing, demand, or clinical/earnings datapoints that would materially reset valuation immediately.
What to watch
For SPCX, the key swing factor is whether earnings include new financial metrics or guidance, which the article does not provide; for the biotechs, investor focus will likely shift to underwriting terms and any updated trial enrollment timelines not mentioned here.
Background
Renaissance Capital previews four scheduled IPOs for the coming week and flags SpaceX earnings plus multiple lock-up expirations.
Ticker impact
SpaceX is highlighted as reporting earnings for the first time as a public company, ahead of a partial lock-up release that more than doubles tradable float.
Higher near-term volatility risk; direction depends on earnings quality versus market expectations.
The article flags two time-linked catalysts (first public earnings and lock-up float expansion) but provides no earnings numbers or guidance.
Braveheart Bio is scheduled to raise $300 million at a $1.4 billion market cap, with Phase 3 plans for obstructive HCM in 2H26 and non-obstructive HCM in 1H27.
IPO-related price discovery likely volatile; longer-term bias tied to Phase 3 execution.
The piece is a calendar/preview with no pricing details beyond headline valuation and no trial results.
Attovia Therapeutics plans to raise $200 million at a $649 million market cap, with Phase 2 planned for 1H27 after Phase 1 dosing in 1Q26.
Likely IPO pop or sell-off depending on demand; medium-term sensitivity to Phase 2 readiness.
No underwriting terms, no investor demand indicators, and no new clinical data are provided.
Vogenx plans to raise $75 million at a $173 million market cap, with Phase 2b screening for PBH expected to begin this year and gastroparesis POC in 2027.
IPO trading likely driven by perceived probability of PBH Phase 2b initiation and timeline credibility.
No efficacy/safety readouts are included, only plans and licensing background.
Market effects
Biotech IPO supply (three names) may concentrate near-term risk appetite in early-stage clinical stories; bank IPO adds CRE-credit sensitivity to the mix.
US-focused IPO calendar with a California bank; limited direct regional spillover beyond investor positioning.
Limited global impact; SpaceX is the only mega-issuer with broader attention, but the article provides no international deal or regulatory developments.
Counterpoint
IPO calendars often overstate near-term tradability; without pricing, demand signals, or new clinical/earnings data, post-IPO performance can diverge sharply from the narrative.
Key entities
- companySpaceX
Mega-issuer expected to report earnings as a public company and face a partial lock-up release that more than doubles tradable float.
- companyBraveheart Bio
Cardiovascular biotech IPO preview with planned Phase 3 timelines for obstructive and non-obstructive HCM.
- companyAttovia Therapeutics
Immune system biotech IPO preview with Phase 2 planned for 1H27 after Phase 1 dosing.
- companyRiver City Bank
California bank IPO preview with CRE loans about 90% of its loan portfolio as of June 30, 2026.
- companyVogenx
Metabolic disorder biotech IPO preview with Phase 2b screening for PBH expected to begin this year.
